ACADIA Pharmaceuticals Inc. (ACAD) News
Filter ACAD News Items
ACAD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACAD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ACAD News From Around the Web
Below are the latest news stories about ACADIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACAD as an investment opportunity.
Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. Driven […] |
Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders should be happy to see the share price up 19% in the last... |
Why ACADIA Pharmaceuticals Inc. (ACAD) Is SkyrocketingWe recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the last day of the year, with Wall Street’s main […] |
Acadia Pharmaceuticals Set to Join S&P SmallCap 600Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. |
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025SAN DIEGO, December 19, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. |
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, December 16, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units ("RSUs") to thirteen new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees |
High Growth Tech Stocks To Watch In December 2024The United States market has remained flat over the last week but is up 29% over the past year, with earnings expected to grow by 15% per annum. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation while aligning with broader market trends. |
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionSAN DIEGO, December 11, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds, pursuant to a license agreement between the companies. |
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial OfficerSAN DIEGO, December 09, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia’s CEO, and serve on the executive leadership team. |
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |